About
Optogenetics for vision restoration: RTx-015 delivers a light-sensitive protein so surviving retinal cells can signal after photoreceptors are lost. RMAT designation (Apr 2026); Series B funding the pivotal trial.
HQ: Berkeley, CA, USA
Funding
$100M Series A (2024) + $125M Series B (Apr 2026)
Plus $12M in CIRM grants.